Table 2.
Effect of omerga-3 on glycemic control, lipid profile, inflammatory biomarkers and oxidative stress biomarkers
| Variables | Number of effect sizes | Weighted Mean Difference | Confidence Interval 95% | P-value | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
| I-squared (%) | P-value | ||||||
| Glycemic control | FPG | 6 | 0.11 | -2.52, 2.74 | 0.935 | 71.8% | 0.003 |
| Insulin | 6 | -0.79 | -2.24, 0.66 | 0.285 | 54.3% | 0.053 | |
| HOMA-IR | 4 | -0.56 | -1.38, 0.26 | 0.181 | 80.3% | 0.002 | |
| Lipid profile | TC | 7 | 5.36 | -2.83, 13.56 | 0.200 | 77.3% | < 0.001 |
| TG | 6 | -8.38 | -27.01, 10.24 | 0.378 | 88.4% | < 0.001 | |
| LDL-C | 5 | 11.98 | -0.04, 24.00 | 0.051 | 78.1% | 0.001 | |
| HDL-C | 6 | 3.10 | 0.18, 6.03 | 0.038 | 87.2% | < 0.001 | |
| TC/HDL | 3 | -0.15 | -0.35, 0.06 | 0.157 | 73.0% | 0.025 | |
| oxidative stress and Inflammatory biomarkers | CRP | 4 | -1.85 | -2.61, -1.09 | < 0.001 | 28.0% | 0.244 |
| IL-6 | 4 | -5.40 | -13.87, 3.08 | 0.212 | 98.7% | < 0.001 | |
| IL-8 | 3 | 0.09 | -0.54, 0.71 | 0.780 | 0.0% | 0.855 | |
| MDA | 3 | -0.39 | -1.43, 0.66 | 0.470 | 90.1% | < 0.001 | |
FPG, fasting plasma glucose; HOMA IR, homeostasis model assessment of insulin resistance; QUICKI, quantitative insulin-sensitivity check index; TC, total cholesterol; TG, triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; CRP, C-Reactive Protein; IL, interleukin; MDA, malondialdehyde